Is Switzerland Still a Lucrative Place for Manufacturers of Drug Substances to Produce Their Products?
DOI:
https://doi.org/10.2533/000942905777676894Keywords:
Api manufacturer, China, Healthcare reform, Pricing pressure, Siegfried, SwitzerlandAbstract
Pharmaceutical manufacturers are coming under increasing pricing pressure as a result of healthcare reforms and are therefore looking to low wage countries in the Far East. Often, the outcome is a process that is not fully mature in economic terms. Contract synthesis manufacturers, such as Siegfried, offer assistance here with its comprehensive pharmaceutical know-how in order to establish efficient and low-cost processes at an early stage. Siegfried's strengths lie in its many years experience in the pharmaceutical industry and in the network of contacts it has built up over the years with technical and material suppliers. Therefore, as far as Switzerland as a location for manufacturing is concerned, Siegfried looks to the future with confidence.Downloads
Published
2005-01-01
Issue
Section
Scientific Articles
License
Copyright (c) 2005 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
[1]
H.-D. Bäuerle, Chimia 2005, 59, 28, DOI: 10.2533/000942905777676894.